<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700229</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-AHA-001</org_study_id>
    <nct_id>NCT03700229</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A</brief_title>
  <official_title>An Open-label Phase II Study to Determine the Efficacy and Safety of Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective study is to determine the efficacy and safety of Rituximab
      plus Bortezomib in patients with newly diagnosed acquired hemophilia A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, open-label clinical trial to evaluate the efficacy and
      safety the regimen of Bortezomib with rituximab as first-line treatment to eradicate
      anti-factor VIII antibodies in newly diagnosed acquired hemophilia A.

      All of enrolled patients in this study will be injected Bortezomib plus rituximab. This study
      will be performed for about 2 years and approximately 22 patients will be enrolled in our
      insititution.

      After obtaining the written informed consent from the patients, the information of
      demographic and medical history will be collected and laboratory tests will be performed.

      Patients who meet the inclusion/exclusion criteria will be received the regimens: Bortezomib
      (1.3mg/m2 d1,4,8,11) with rituximab (375mg/m2 for one dose). The information of adverse
      events will be collected. In case that the evaluation of treatment response might be
      performed in regular clinical practice, those data will also be collected as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to attain first complete remission (CR)</measure>
    <time_frame>Last day of the treatment regimen (up to 3 months)</time_frame>
    <description>Complete remission defined as titer FVIII inhibitor lower than 0.6 Bethesda unit, factor VIII level&gt; 50% and no bleeding events without bypass treatments for 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to durable treatment response</measure>
    <time_frame>During 24 month</time_frame>
    <description>The time to durable treatment response was defined as the time from date of achieving CR until the date of relapse or date of death from any cause（whichever came first）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During 24 month</time_frame>
    <description>Include major bleeding, infection, nerve toxicity, and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>During 24 month</time_frame>
    <description>Overall survival was defined as the time from date of first diagnosis until the date of death from any cause，and death from any cause will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Acquired Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Bortezomib +Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib +Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses</description>
    <arm_group_label>Bortezomib +Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>rituximab intravenously 500 mg for one dose</description>
    <arm_group_label>Bortezomib +Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be ≥ 18 years;

          2. Understand and voluntarily sign an ICD prior to any study related
             assessments/procedures are conducted;

          3. Diagnosis of acquired hemophilia A；

          4. acute bleeding episodes(≥once).

        Exclusion Criteria:

          1. Uncontrolled systemic infection;

          2. Allergy to rituximab;

          3. Positive for Lupus anticoagulant;

          4. Life expectancy &lt; 3 months;

          5. Pregnant and breastfeeding women;

          6. Neuropathy&gt;Grade 1;

          7. Positive for Hepatitis B surface antigen or hepatitis C antibody or human
             immunodeficiency virus（HIV）antibody;

          8. Patients with poor compliance；

          9. Patient who is considered by the investigator not suitable for clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tienan Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huacong Cai</last_name>
    <phone>01069158271</phone>
    <email>caihc@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tienan Zhu</last_name>
    <phone>01069158271</phone>
    <email>zhutn@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huacong Cai</last_name>
      <phone>01069158271</phone>
      <email>caihc@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tienan Zhu, MD</last_name>
      <phone>01069158271</phone>
      <email>zhutn@pumch.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Tienan Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kühne A; EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012 Jul 5;120(1):47-55. doi: 10.1182/blood-2012-02-409185. Epub 2012 Apr 18.</citation>
    <PMID>22517903</PMID>
  </reference>
  <reference>
    <citation>Brás GP, Pinto RJ, Carvalho MM, Fernandes SP, Andrade JJ, Guimarães JE. Bortezomib: Potential Key Role in the Treatment of Multiple Myeloma-Related Acquired Hemophilia A. Semin Thromb Hemost. 2017 Feb;43(1):109-112. doi: 10.1055/s-0036-1597648. Epub 2016 Dec 19.</citation>
    <PMID>27992938</PMID>
  </reference>
  <reference>
    <citation>Bonfanti C, Crestani S, Frattini F, Sissa C, Franchini M. Role of rituximab in the treatment of postpartum acquired haemophilia A: a systematic review of the literature. Blood Transfus. 2015 Jul;13(3):396-400. doi: 10.2450/2014.0242-14. Epub 2014 Dec 17. Review.</citation>
    <PMID>25545867</PMID>
  </reference>
  <results_reference>
    <citation>Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv. 2016 Nov 22;1(1):31-35. doi: 10.1182/bloodadvances.2016001412. eCollection 2016 Nov 29.</citation>
    <PMID>29296693</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Tienan Zhu</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

